Marie José Kersten1,2, Anne Mea Spanjaart1, Catherine Thieblemont3,4. 1. Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam. 2. Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands. 3. Department of Hemato-Oncology, Hôpital Saint-Louis. 4. Diderot University, Paris, France.
Abstract
PURPOSE OF REVIEW: CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a valuable new treatment option for patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. The aim of this review is to give an overview of the pivotal phase I/II trials, emerging real-world evidence and ongoing trials. RECENT FINDINGS: For decades, attempts at improvement of the poor prognosis of patients with R/R large B-cell lymphoma with new treatment regimens have been disappointing. Since the first report of CD19-directed CAR-T-cell therapy in 2010, three constructs have been tested in large phase I/II trials and resulted in 30-40% durable responses. This has led to Food and Drug Administration and European Medicines Agency approval for axicabtagene ciloleucel and tisagenlecleucel and filing of the biologics license application for lisocabtagene maraleucel. Emerging real-world evidence seems to confirm the promising results. However, considerable toxicity, mainly cytokine release syndrome and neurotoxicity limits their general applicability and not all patients intended to be treated can be bridged during the manufacturing period due to kinetics of the disease. Randomized phase III clinical trials are being conducted to test anti-CD19 CAR-T-cell therapy in the second-line and several phase II trials are aiming to improve efficacy and decrease toxicity. SUMMARY: CD19-directed CAR-T-cell therapy has become standard of care for aggressive R/R diffuse large B-cell non-Hodgkin lymphoma (DLBCL), but challenges still remain.
PURPOSE OF REVIEW: CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a valuable new treatment option for patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. The aim of this review is to give an overview of the pivotal phase I/II trials, emerging real-world evidence and ongoing trials. RECENT FINDINGS: For decades, attempts at improvement of the poor prognosis of patients with R/R large B-cell lymphoma with new treatment regimens have been disappointing. Since the first report of CD19-directed CAR-T-cell therapy in 2010, three constructs have been tested in large phase I/II trials and resulted in 30-40% durable responses. This has led to Food and Drug Administration and European Medicines Agency approval for axicabtagene ciloleucel and tisagenlecleucel and filing of the biologics license application for lisocabtagene maraleucel. Emerging real-world evidence seems to confirm the promising results. However, considerable toxicity, mainly cytokine release syndrome and neurotoxicity limits their general applicability and not all patients intended to be treated can be bridged during the manufacturing period due to kinetics of the disease. Randomized phase III clinical trials are being conducted to test anti-CD19CAR-T-cell therapy in the second-line and several phase II trials are aiming to improve efficacy and decrease toxicity. SUMMARY:CD19-directed CAR-T-cell therapy has become standard of care for aggressive R/R diffuse large B-cell non-Hodgkin lymphoma (DLBCL), but challenges still remain.
Authors: Zachary Jackson; Changjin Hong; Robert Schauner; Boro Dropulic; Paolo F Caimi; Marcos de Lima; Maria Florencia Giraudo; Kalpana Gupta; Jane S Reese; Tae Hyun Hwang; David N Wald Journal: Cancer Discov Date: 2022-08-05 Impact factor: 38.272
Authors: Bart E K S Swinnen; Anne-Fleur van Rootselaar; Anne M Spanjaart; Rob M A de Bie; Marie J Kersten; Diederik van de Beek; Matthijs C Brouwer; Joke M Dijk Journal: J Neurol Date: 2022-04-11 Impact factor: 6.682
Authors: Carlos A Garcia-Prieto; Lorea Villanueva; Alberto Bueno-Costa; Veronica Davalos; Europa Azucena González-Navarro; Manel Juan; Álvaro Urbano-Ispizua; Julio Delgado; Valentín Ortiz-Maldonado; Francesca Del Bufalo; Franco Locatelli; Concetta Quintarelli; Matilde Sinibaldi; Marta Soler; Manuel Castro de Moura; Gerardo Ferrer; Rocio G Urdinguio; Agustin F Fernandez; Mario F Fraga; Diana Bar; Amilia Meir; Orit Itzhaki; Michal J Besser; Abraham Avigdor; Elad Jacoby; Manel Esteller Journal: J Natl Cancer Inst Date: 2022-03-08 Impact factor: 13.506